Telix Pharmaceuticals Ltd ADR Dossier - Source-backed chat

Telix Pharmaceuticals Ltd ADR

TLXAustralian Securities Exchange

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.74

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.97Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $3.7B

Enterprise Value $4B

Moat Rating None

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Telix Pharmaceuticals is transitioning rapidly from a pre-commercial biotech to a highly successful, vertically integrated global leader in precision oncology and theranostics. Driven by its flagship PSMA imaging franchise (Illuccix) and strategic acquisitions like RLS Radiopharmacies, the company has achieved robust top-line growth (56% YoY in FY25 to $804M) and is self-funding its extensive late-stage pipeline. With multiple near-term regulatory catalysts in late 2026, including the FDA PDUFA date for Pixclara and expected clearance for Zircalix, Telix is well-positioned to capture significant market share in the expanding radiopharmaceutical sector.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$19.84

Mean target$21.22

High · most bullish analyst$22.40

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$19.84

Regulatory delays or requests for additional clinical data from the FDA for Pixclara or Zircalix dampen investor sentiment. Increased competition in the PSMA imaging market from established players like Lantheus puts pressure on pricing and margins, while elevated R&D and integration expenses lead to wider-than-expected net losses.

Base CaseCentral scenario

$21.22

Matches the consensus mean

Telix successfully delivers on its FY26 revenue guidance of $950M to $970M, supported by steady growth in its core Precision Medicine segment and a full-year contribution from RLS Radiopharmacies. Pixclara receives FDA approval on its September 11, 2026 PDUFA date, and Zircalix progresses through the regulatory pipeline. R&D spending remains within the guided $200M to $240M range, maintaining a healthy cash balance.

Bull CaseUpside scenario

$22.40

Accelerated FDA approvals for both Pixclara and Zircalix, combined with rapid market penetration of Illuccix in newly entered regions like China, drives FY26 revenues above the high end of guidance ($970M+). The Regeneron collaboration yields early clinical milestones, and the Phase 3 ProstACT Global trial progresses ahead of schedule, sparking potential acquisition interest from global pharma giants.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum with 56% YoY revenue growth in FY25 and clear FY26 guidance of $950M to $970M.
Differentiated theranostic portfolio integrating companion diagnostics and targeted therapies across prostate, kidney, and brain cancers.
Robust global supply chain and manufacturing network with over 50 locations, ensuring vertical integration and reliable delivery.
Strategic global collaboration with Regeneron, providing $40M upfront and up to $2.1B in potential milestones.

Key Investment Risks

High regulatory dependency with critical FDA decisions pending for Pixclara and Zircalix.
Intense competition in the radiopharmaceutical space from well-funded global pharmaceutical giants like Novartis and Lantheus.
Execution and integration risks associated with recent rapid acquisitions (e.g., RLS Radiopharmacies, ARTMS, IsoTherapeutics).
Historical net losses and cash burn from heavy R&D and capital expenditures before reaching sustained profitability.

Thesis Invalidation Triggers

FDA rejection or significant delay of Pixclara (TLX101-Px) beyond the September 11, 2026 PDUFA date.
Failure to resolve FDA requests for additional data regarding the Zircalix kidney cancer imaging candidate.
A severe contraction in operating margins or a failure to meet the guided FY26 revenue range of $950M to $970M.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.